Reducing Number of Patient Visits and Time to Biopsy After Suspicious Breast MRI

Author(s):  
W.T. Rahman ◽  
Sarah E.H. Moorman ◽  
Colleen H. Neal ◽  
Rebecca A. Hall ◽  
Heather L. Cheasick ◽  
...  
Keyword(s):  
Ob Gyn News ◽  
2005 ◽  
Vol 40 (6) ◽  
pp. 16
Author(s):  
BRUCE JANCIN
Keyword(s):  

2011 ◽  
Author(s):  
Jeremy Price
Keyword(s):  

2020 ◽  
pp. 25-31
Author(s):  
M. L. Mazo ◽  
O. E. Jacobs ◽  
O. S. Puchkova ◽  
M. V. Feldsherov ◽  
E. V. Kondratyev

The rate of detection of breast cancer by MRI, while other methods of radiological diagnosis are not sufficiently informative, ranges from 5.2 to 26.3 per cent. Suspicious breast tumors of category BI-RADS 4, 5 show morphological image-guided biopsy verification, in particular MRI with contrast. Purpose. To show the possibilities and features of carrying out MRI-guided vacuum breast biopsy, including after aesthetic breast augmentation. Material and methods. A comprehensive X-ray, ultrasound and MRI examination of 54 women aged between 28 and 70 years with different breast tumors was conducted. Of these, five were detected only by breast MRI with contrast, and were morphologically verified by MRI-guided vacuum aspiration biopsy. Results. 14 of the 54 patients with breast mass were diagnosed with breast cancer and 26 were diagnosed with benign diseases. The effectiveness of comprehensive examination and low-invasive high-tech MRI-guided procedures in early refined screening for breast cancer, including after aesthetic breast augmentation, has been demonstrated. MRI-guided vacuum-assisted breast biopsy is a fast, safe and accurate diagnostic method of morphological verification of suspicious breast tumors that do not have X-ray and ultrasound.


2019 ◽  
Vol 1 (1) ◽  
pp. 64-72 ◽  
Author(s):  
Jordana Phillips ◽  
Valerie J Fein-Zachary ◽  
Priscilla J Slanetz

Abstract Contrast-enhanced mammography (CEM) is a promising new imaging modality that uses a dual-energy acquisition to provide both morphologic and vascular assessment of breast lesions. Although no official BI-RADS lexicon exists, interpretation entails using the mammographic BI-RADS lexicon in combination with that for breast MRI. CEM has comparable performance to breast MRI, with sensitivity of 93–100% and specificity of 80–94%. Currently FDA approved for diagnostic imaging, this technology can be helpful in determining disease extent in patients with newly diagnosed breast malignancy, monitoring response to neoadjuvant therapy, identifying mammographically occult malignancies, and diagnostic problem-solving. Studies are ongoing about its role in screening, especially in women with dense breasts or at elevated risk. There are some challenges to successful implementation into practice, but overall, patients tolerate the study well, and exam times are less than the full breast MRI protocol.


Author(s):  
Martine Boisserie-Lacroix ◽  
Isabelle Doutriaux-Dumoulin ◽  
Jocelyne Chopier ◽  
Bruno Boyer ◽  
Marie-Pierre Depetiteville ◽  
...  

2020 ◽  
Author(s):  
Viktor Puchnin ◽  
Anna Hurshkainen ◽  
Georgiy Solomakha ◽  
Anna Andreychenko ◽  
Alena Shchelokova
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document